Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 12 of 110 Updated Nov 17, 2026

Somatropin (HGH)

Recombinant hGH · Humatrope · Genotropin · Norditropin

FDA-APPROVED · RECOMBINANT HUMAN GROWTH HORMONE

▓ 213 indexed citations across PubMed (141), ClinicalTrials.gov (29), EuropePMC (43).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

213 citations across 8 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Direct GH receptor agonist; induces IGF-1 synthesis; promotes anabolism and lipolysis

Researched effects

Direct GH effects; lean mass; fat loss; bone density; approved for GHD/Turner/etc.

Reported efficacy (trial readout)

  • Growth Velocity 11.2 cm/year

    Somapacitan REAL4 phase (Phase 3, 52wk)

    High confidencePhase 3

Trial-efficacy data current as of November 16, 2026.

Live evidence

FDA label safety

Contraindications

4 CONTRAINDICATIONS HUMATROPE is contraindicated in patients with: Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see Warnings and Precautions ( 5.1 )] . Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to the risk of sudden death [see Warnings and Precautions ( 5.2 )] . Active malignancy [see…

Full FDA label (DailyMed) →

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

0.15 mg SC daily (Genotropin adult GHD label starting dose, titrate by IGF-1 response to 0.3 mg/day per AACE 2019 guideline); 1-2 IU/day anti-aging off-label

→ FDA Genotropin/Norditropin prescribing information (adult GHD starting dose); AACE 2019 GH guideline (Yuen et al., PMID 31760104)

Known concerns

Insulin resistance; edema; carpal tunnel; arthralgia; acromegaly if overdosed

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Once-weekly somapacitan vs. daily norditropin in GHD: a systematic review and meta-analysis of efficacy and safety in children and adults.

    Endocrine · 2026 — META-ANALYSES · AUTHORITY 94.5

  2. Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials.

    Endocrine · 2024 — META-ANALYSES · AUTHORITY 94.4

  3. Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.

    Children (Basel, Switzerland) · 2024 — META-ANALYSES · AUTHORITY 94.4

  4. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.

    Pharmacological research · 2023 — META-ANALYSES · AUTHORITY 94.3

  5. Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin

    Clinical pharmacokinetics · 2021 — META-ANALYSES · AUTHORITY 94.1

  6. The effectiveness and safety of recombinant human growth hormone combined with alginate dressing in the treatment of diabetic foot ulcer: A protocol for systematic review and meta-analysis.

    2021 — META-ANALYSES · AUTHORITY 94.1

  7. Pediatric growth hormone treatment in Italy: A systematic review of epidemiology, quality of life, treatment adherence, and economic impact.

    2022 — SYSTEMATIC REVIEWS · AUTHORITY 84.2

  8. Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature.

    Journal of pediatric endocrinology & metabolism : JPEM · 2010 — SYSTEMATIC REVIEWS · AUTHORITY 83.0

  9. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.

    The Journal of clinical endocrinology and metabolism · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 78.2

  10. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.

    The Journal of clinical endocrinology and metabolism · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 78.2

Full citation library

Year distribution

Meta-Analyses

6
  1. 1.

    Mameli C, Orso M, Calcaterra V, Wasniewska MG, et al. · Pharmacological research · 2023 · PMID 37236413

    We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the treatment of growth hormone deficiency (GHD) in children. Systematic searches were performed in PubMed, Embase and Web of Science up to July 2022 on randomized and non-randomized studies involving children with GHD receiving LAGH as compared to daily GH. Meta-analyses for efficacy and safety were performed comparing diffe…

  2. 2.

    Altobaishat O, Abouzid M, Moawad MHED, Sharaf A, et al. · Endocrine · 2024 · PMID 38658475

    Growth hormone deficiency occurs when the pituitary gland does not produce enough growth hormone. Norditropin®, a recombinant human growth hormone, and Sogroya®, an albumin-binding growth hormone derivative, are prescribed for patients with growth hormone deficiency. This systematic review assesses the efficacy, safety, and patient satisfaction associated with Norditropin and Sogroya. We systematically searched PubMed, Web of Science, and Scopus databases to identify eligible comparative studies…

  3. 3.

    Papathanasiou T, Agersø H, Damholt BB, Højby Rasmussen M, et al. · Clinical pharmacokinetics · 2021 · PMID 33864240

    Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin A model was developed based on a population PK/PD modelling meta-analysis of data from three phase I clinical trials (two using Norditropin The model developed accurately describes and predicts GH pharmacokinetics and IGF-I response. Body weight was shown to have an important inversely correlated influence on GH exposure (and IGF-I standard deviation score), and this largely explained differences between a…

  4. 4.

    Azhar S, Daniyal M, Memon RR, Sajid H, et al. · Endocrine · 2026 · PMID 42081070

  5. 5.

    Tsurayya G, Nazhifah CA, Pirwanja MR, Zulfa PO, et al. · Children (Basel, Switzerland) · 2024 · PMID 38397339

    Growth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates. Once-weekly Somapacitan is a potential alternative for treating children with GHD. This study aimed to evaluate the efficacy, safety, and adherence of once-weekly subcutaneous Somapacitan compared to daily growth hormone injection in prepubertal ch…

  6. 6.

    Zhou DR, Deng HY, Pu LL, Lin SL, Gou R, Wang FL. · 2021 · PMID 33592853

    <h4>Background</h4>Diabetic foot ulcer (DFU) is one of the serious complications of diabetes. It is the result of a joint effect of lower extremities vascular lesions, neuropathy, and infection, which require amputation and even threaten the life of the patient. At present, the conventional treatment for DFU includes infection control, wound care, wound reduction, reduction of foot pressure, use of dressings that are beneficial to wound surface healing, etc, but the effectiveness is not satisfac…

Systematic Reviews

2
  1. 7.

    Loftus J, Heatley R, Walsh C, Dimitri P · Journal of pediatric endocrinology & metabolism : JPEM · 2010 · PMID 20662327

    Genotropin (somatropin) is licensed for the treatment of children with growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency and in children born small for gestational age. This systematic review (SR) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children. Search terms were used to search seven databases, including Medline a…

  2. 8.

    Orso M, Polistena B, Granato S, Novelli G, Di Virgilio R, La Torre D, d'Angela D, Spandonaro F. · 2022 · PMID 35213607

    <h4>Objectives</h4>This systematic review aims to describe 1) the epidemiology of the diseases indicated for treatment with growth hormone (GH) in Italy; 2) the adherence to the GH treatment in Italy and factors associated with non-adherence; 3) the economic impact of GH treatment in Italy; 4) the quality of life of patients treated with GH and their caregivers in Italy.<h4>Methods</h4>Systematic literature searches were performed in PubMed, Embase and Web of Science from January 2010 to March 2…

Randomised Controlled Trials

29
  1. 9.

    Miller BS, Blair JC, Rasmussen MH, Maniatis A, et al. · The Journal of clinical endocrinology and metabolism · 2022 · PMID 36062966

    Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). To demonstrate efficacy and safety of somapacitan vs daily GH. REAL4 is a randomised, multinational, open-labeled, active-controlled parallel group phase 3 trial, comprising a 52-week main trial and 3-year extension (NCT03811535). Eighty-six sites across 20 countries. 200 treatment-naïve patients were randomized and exposed. Patients were randomized 2:1 to somapacitan (0.16 mg/…

  2. 10.

    Miller BS, Blair JC, Rasmussen MH, Frystyk J, et al. · European journal of endocrinology · 2025 · PMID 40400262

    Somapacitan is a long-acting GH approved for once-weekly treatment of GH deficiency (GHD). This study aims to evaluate the efficacy and tolerability of somapacitan after 3 years of treatment and 2 years after switch from daily GH in children with GHD. Randomized, multi-national, open-labelled, active-controlled parallel-group phase 3 trial, with a 52-week main phase and 3-year safety extension (NCT03811535). Treatment-naïve children with GHD were randomized (2:1) to continuous somapacitan (0.16…

  3. 11.

    Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, et al. · Hormone research in paediatrics · 2022 · PMID 35417909

    Somatrogon is a long-acting recombinant human growth hormone being developed as a once-weekly treatment for children with growth hormone deficiency (GHD). The objective of this phase 3 study (NCT03874013) was to compare the efficacy and safety of once-weekly somatrogon with once-daily Genotropin in Japanese children with GHD. In this open-label, randomized, active-controlled study, 44 prepubertal Japanese children with GHD (boys: 3 to <11 years; girls: 3 to <10 years) were randomized 1:1 to rece…

  4. 12.

    Pfützner A, Hartmann K, Winter F, Fuchs GS, et al. · Clinical therapeutics · 2010 · PMID 21095487

    Growth hormone (GH) is used to treat pediatric and adult GH deficiency (GHD) and growth failure in, among others, patients with Turner syndrome or children born small for gestational age. To improve treatment adherence, self-injection devices should be easy to learn, easy to use, and well accepted, especially in pediatric patients. Several GH pen devices are available, each with distinct features designed for specific patient needs. This study compared injection time and intuitiveness of a prefi…

  5. 13.

    Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, Romer T, et al. · Hormone research · 2007 · PMID 17627092

    Valtropin is a recombinant human GH (rhGH) manufactured using a novel yeast expression system, classed as a 'biosimilar'. Valtropin was compared with Humatrope in children with GH deficiency (GHD). Treatment-naive, prepubertal children with GHD were randomized to Valtropin (n = 98) or Humatrope (n = 49) for 1 year. Standing height was measured 3-monthly and height velocity (HV) calculated. Serum IGF-I, IGFBP-3 and GH antibodies were determined centrally. HV at 1 year was 11.3 +/- 3.0 cm/year wit…

  6. 14.

    Otsuka F, Rasmussen MH, Endo T, Sværke C, et al. · Frontiers in endocrinology · 2025 · PMID 39991735

    Somapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD. This subgroup study included the 34-week main period of the multinational, randomized, parallel-group, phase 3 trial, REAL 1 (NCT02229851). Participants received once-weekly somapacitan or daily GH (Norditropin In total, 36 Japanese individuals were included…

  7. 15.

    Müller J, Skakkebaek NE, Jacobsen BB, Keller E, et al. · Hormone research · 1999 · PMID 10592453

    Patient compliance is of vital importance for the outcome of any medical therapy. Compliance is especially a problem in long-term treatment of non-life threatening diseases, such as growth retardation in children. Until recently, all human growth hormone (hGH) products required a reconstitution process. Norditropin((R)) SimpleXx(TM) is a liquid formulation of the biosynthetic hGH product Norditropin((R)), and, together with an improved NovoPen((R)) 1.5, NordiPen(TM), and an auto-insertion device…

  8. 16.

    Dörr HG, Zabransky S, Keller E, Otten BJ, et al. · Journal of pediatric endocrinology & metabolism : JPEM · 2003 · PMID 12705363

    The clinical safety, use and pharmacokinetics of a new needle-free device for delivery of growth hormone (GH) were compared with those of conventional needle injection devices. In an open-label, randomized, 4-period crossover study, 18 healthy adults received single subcutaneous injections of Genotropin administered by the Genotropin ZipTip needle-free device and by conventional injection. Bioequivalence was established between the devices. In a separate open-label, randomized, multicenter, 2-pe…

  9. 17.

    Ozono K, Ogata T, Horikawa R, Matsubara Y, et al. · Endocrine journal · 2018 · PMID 29109363

    This randomized double-blind multicenter trial (NCT01927861) evaluated the growth-promoting effect and safety of Norditropin

  10. 18.

    Czepielewski MA, Garret Q, Vencio SAC, Rassi N, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2019 · PMID 31493626

    The CERES study was a randomized, multicenter, investigator-blind trial aimed to evaluate the efficacy and safety of a recombinant human growth hormone (r-hGH) developed by Cristalia, as a biosimilar product, with analytical, functional and pharmacokinetics similarities comparable to Genotropin™, in children with growth hormone deficiency (GHD). A total of 135 naïve prepubertal children with GHD were recruited, of whom 97 were randomized in 14 Brazilian sites to received either r-hGH Cristalia (…

  11. 19.

    Zadik Z, Zelinska N, Iotova V, Skorodok Y, et al. · Journal of pediatric endocrinology & metabolism : JPEM · 2023 · PMID 36732285

    Somatrogon is a long-acting recombinant human growth hormone (GH) employed as a once-weekly treatment for children with GH deficiency (GHD). A 12-month, phase 2 study of once-weekly somatrogon vs. once-daily GH (Genotropin There were five study periods, Periods I and II were 6 months each while Periods III, IV, and V were 12 months each. In the main study (Periods I and II), 53 prepubertal children with GHD were randomized to once-weekly somatrogon (0.25, 0.48, or 0.66 mg/kg/week) or once-daily…

  12. 20.

    Johannsson G, Feldt-Rasmussen U, Håkonsson IH, Biering H, et al. · European journal of endocrinology · 2018 · PMID 29500310

    Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin 26-week randomized, controlled phase 3 safety and tolerability trial in six countries (Nbib2382939). Male or female patients aged 18-79 years with adult GH deficiency (AGHD), treated with once-daily GH for ≥6 months, were randomized to once-weekly somapacitan ( Mean IGF-I SDS remained bet…

  13. 21.

    Horikawa R, Ogata T, Matsubara Y, Yokoya S, et al. · Endocrine journal · 2020 · PMID 32269181

    This 4-year randomized, double-blind, multicenter trial (NCT01927861) investigated the long-term efficacy and safety of Norditropin

  14. 22.

    Peng H, Shang W, Lin Y, Xu J, et al. · European journal of endocrinology · 2025 · PMID 40576382

    Growth hormone deficiency (GHD) requires long-term treatment, but daily injections and adverse effects of current therapies often pose adherence challenges in children. GB08, a novel Fc-GH, leverages the extended half-life of Fc-fusion proteins to reduce injection frequency with potential for improved safety. This study evaluates the safety, immunogenicity, pharmacokinetics, and pharmacodynamics profiles of GB08 in healthy adults. The findings, along with population PK/PD modeling, will guide do…

  15. 23.

    Kim SJ, Kim MS, Cho SY, Suh BK, et al. · Medicine · 2021 · PMID 34397702

    Growth hormone (GH) treatment is known to be effective in increasing stature in children with a short stature born small for gestational age (SGA). This multicentre, randomized, open-label, comparative, phase III study aimed to evaluate the efficacy and safety of Growtropin-II (recombinant human GH) and to demonstrate that the growth-promoting effect of Growtropin-II is not inferior to that of Genotropin in children with SGA (NCT ID: NCT02770157). Seventy five children who met the inclusion crit…

  16. 24.

    Ku CR, Brue T, Schilbach K, Ignatenko S, et al. · European journal of endocrinology · 2018 · PMID 29973375

    Hybrid Fc-fused rhGH (GX-H9) is a long-acting recombinant human growth hormone (GH) under clinical development for both adults and children with GH deficiency (GHD). We compared the safety, pharmacokinetics and pharmacodynamics of weekly and every other week (EOW) dosages of GX-H9 with those of daily GH administration in adult GHD (AGHD) patients. This was a randomized, open-label, active-controlled and dose-escalation study conducted in 16 endocrinology centers in Europe and Korea. Forty-five A…

  17. 25.

    Equey T, Pastor A, de la Torre Fornell R, Thomas A, et al. · The Journal of clinical endocrinology and metabolism · 2022 · PMID 34726230

    Because of its anabolic and lipolytic properties, growth hormone (GH) use is prohibited in sport. Two methods based on population-derived decision limits are currently used to detect human GH (hGH) abuse: the hGH Biomarkers Test and the Isoforms Differential Immunoassay. We tested the hypothesis that longitudinal profiling of hGH biomarkers through application of the Athlete Biological Passport (ABP) has the potential to flag hGH abuse. Insulin-like growth factor 1 (IGF-1) and procollagen III pe…

  18. 26.

    Rasmussen MH, Janukonyté J, Klose M, Marina D, et al. · The Journal of clinical endocrinology and metabolism · 2016 · PMID 26727076

    NNC0195-0092 is a reversible, albumin-binding GH derivative, developed for once-weekly administration. The objective of the study was to evaluate safety, local tolerability, pharmacodynamics, and pharmacokinetics of multiple, once-weekly doses of NNC0195-0092, compared with daily GH. This was a phase 1, randomized, open-label, active-controlled, multiple-dose, dose-escalation trial. Thirty-four GH-treated adult subjects (male, n = 25) with GH deficiency participated in the study. Subjects were s…

  19. 27.

    Chatelain P, Malievskiy O, Radziuk K, Senatorova G, et al. · The Journal of clinical endocrinology and metabolism · 2017 · PMID 28201598

    TransCon Growth Hormone (GH) (Ascendis Pharma) is a long-acting recombinant sustained-release human GH prodrug in development for children with GH deficiency (GHD). To compare the pharmacokinetics, pharmacodynamics, safety, and efficacy of weekly TransCon GH to that of daily GH in prepubertal children with GHD. Randomized, open-label, active-controlled study of three doses of weekly TransCon GH versus daily Genotropin (Pfizer). Thirty-eight centers in 14 European countries and Egypt. Prepubertal…

  20. 28.

    Romer T, Saenger P, Peter F, Walczak M, et al. · Hormone research · 2009 · PMID 19844125

    This phase III clinical study in growth hormone deficiency (GHD) children with growth retardation was designed to compare efficacy and safety of Omnitrope((R)) with Genotropin((R)) and assess the long-term safety and efficacy of Omnitrope((R)). The results of 7 years of treatment with Omnitrope((R)) are presented. Eighty-nine treatment-naïve, prepubertal children with GHD were randomized (part 1) to Omnitrope((R)) lyophilisate (group A, n = 44) or Genotropin((R)) (group B, n = 45) for 9 months a…

  21. 29.

    De Schepper J, Vanderfaeillie J, Mullis PE, Rooman R, et al. · Clinical endocrinology · 2016 · PMID 26501737

    In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognitive functioning in very young (<30 months), short-stature children born SGA. A 2-year, randomized controlled, multicentre study (NCT00627523; EGN study), in which patients received either GH treatment or no treatment f…

  22. 30.

    Caidahl K, Edén S, Bengtsson BA · Clinical endocrinology · 1994 · PMID 8187304

    With the advent of recombinant human GH (rhGH), it has become possible in controlled clinical studies to explore the effects of GH replacement in adults with GH deficiency. The objective of this study was to determine cardiovascular and renal effects of GH replacement in adults with GH deficiency. We studied ten patients (one woman and nine men), mean age 47 years, with GH deficiency. The patients were given s.c. rhGH (Humatrope, Eli Lilly) 0.5 U/kg/week or placebo in a 6-month double blind cros…

  23. 31.

    Janssen YJ, Frölich M, Roelfsema F · The Journal of clinical endocrinology and metabolism · 1997 · PMID 8989246

    We investigated the effect of 12 weeks of recombinant human GH therapy given in three different doses on serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) in patients with GH deficiency (GHD). We used low doses of recombinant human GH (Genotropin), as we and others recently found a strong decrease in physiological GH production with age in healthy controls, especially in those older than 30 yr. Sixty patients with GHD (aged 20-70 yr) were randomized to one of the thr…

  24. 32.

    Zaeri H, Omidvar S, Servatian N, Arefnia S, et al. · Expert opinion on drug safety · 2025 · PMID 38682328

    This study is designed in order to compare the efficacy and safety of recombinant human growth hormone (rhGH) with the reference brand. According to the inclusion criteria, 85 people in 13 Iranian centers were randomly selected to receive biosimilar Somatropin (Somatin®) (44 people) and reference Somatropin (Norditropin®) (41 people) at a dose of 35 µg/kg/d, seven days/week for 12 months. The primary outcomes included height velocity (HV) was measured during 12 months of treatment. The two inter…

  25. 33.

    Counts DR, Silverman LA, Geffner ME, Rajicic N, et al. · Hormone research in paediatrics · 2013 · PMID 24021297

    Several models have been developed to predict growth response to growth hormone (GH) based on auxological and biochemical parameters for children with non-GH-deficient, idiopathic short stature (ISS). To demonstrate if an individualized, formula-based, target-driven GH regimen for children with ISS would lead to a height (Ht) gain to -1.3 SDS during the first 24 months of treatment of this 4-year study, with less variability than with standard weight-based dosing. A 4-year, open-label, multi-cen…

  26. 34.

    Fuhr U, Tuculanu D, Berghout A, Balser S, et al. · European journal of endocrinology · 2010 · PMID 20332125

    Two strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients. Omnitrope 3.3 mg/ml solution or Omnitrope 6.7 mg/ml solution was compared to Omnitrope 5 mg/ml powder and Genotropin 5 mg/ml powder in terms of pharmacokinetics, pharmacodynamics, safety, and local tolerance after a single s.c. dose of 5 mg. Two randomized, double-blind, single-dose, three-way crossover studies were carried out in 36 y…

  27. 35.

    Stanhope R, Sörgel F, Gravel P, Pannatier Schuetz YB, et al. · Journal of clinical pharmacology · 2010 · PMID 20173088

    This article discusses the bioequivalence of Omnitrope (Sandoz's rhGH biosimilar) and Genotropin (reference rhGH product), assessed in the first 2 clinical phase 1 studies conducted during the development of Omnitrope. Both of these phase 1 studies were randomized, double-blind, crossover studies, each involving 24 healthy volunteers who underwent pituitary somatrope cell down-regulation using octreotide. Three different formulations of recombinant human growth hormone (rhGH) were compared: Omni…

  28. 36.

    Elgzyri T, Castenfors J, Hägg E, Backman C, et al. · Clinical endocrinology · 2004 · PMID 15212653

    To assess effects of GH replacement therapy on cardiac structure and function, exercise capacity as well as serum lipids in elderly patients with GH deficiency (GHD). Thirty-one patients (six females, 25 males), aged 60-79 years (mean 68 years) with GHD on stable cortisone and thyroxine substitution were studied. All men with gonadotropin deficiency had testosterone and one woman had oestrogen replacement. They were randomized in a double-blind manner to GH or placebo treatment for 6 months, fol…

  29. 37.

    Counts DR, Silverman LA, Rajicic N, Geffner ME, et al. · Hormone research in paediatrics · 2015 · PMID 25966824

    Growth hormone (GH) treatment regimens for children with non-GH-deficient, idiopathic short stature (ISS) have not been optimized. To compare the efficacy, efficiency, and safety of an individualized, target-driven GH regimen with standard weight-based dosing after 4 years of treatment. This is a 4-year, open-label, multicenter, randomized trial comparing individualized, formula-based dosing of Genotropin® versus a widely used ISS dose of Genotropin®. Subjects were prepubertal, had a bone age of…

Clinical Trials

10
  1. 38.

    Shih KC, Ho LT, Kuo HF, Chang TC, et al. · Zhonghua yi xue za zhi = Chinese medical journal; Free China ed · 1994 · PMID 8087727

    This study was to evaluate the efficacy, safety and immunogenicity of recombinant human growth hormone (rhGH) in treatment of children with growth hormone deficiency (GHD). We selected 15 children with GHD for a 12-month clinical trial and separated them into three groups with each 5 patients receiving one of the 3 tested rhGH (Saizen by Serono, Aubonne, Switzerland; Genotropin by KabiVitrum, Stockholm, Sweden and Humatrope by Eli Lilly, Indianapolis, USA). In Saizen group, 3 boys and 2 girls wi…

  2. 39.

    Czepielewski MA, Garret Q, Vencio SAC, Rassi N, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2021 · PMID 33260063

    A previous 12-month comparative trial with Criscy™ (r-hGH Cristália), a biosimilar recombinant growth hormone, demonstrated equivalent efficacy and safety to Genotropin™. This extension trial evaluated the effects of switching patients treated with Genotropin™ to the biosimilar Criscy™ over an additional 6-month treatment period, comparing efficacy, safety, and immunogenicity parameters with patients remaining in the Criscy™ arm. This extension study included 11 research centers and 81 patients…

  3. 40.

    Kappelgaard AM, Mikkelsen S, Knudsen TK, Fuchs GS · Journal of pediatric endocrinology & metabolism : JPEM · 2011 · PMID 21932587

    Growth hormone deficiency (GHD) in children is treated with daily subcutaneous injections of GH. Poor adherence, resulting in suboptimal treatment outcomes, is common due to long-term treatment. Injection devices that are considered easy to use by patients or guardians could improve adherence. This study assessed the usability of the Norditropin FlexPro pen injector and NovoTwist needles (both Novo Nordisk A/S, Bagsvaerd, Denmark) in Japanese children and adolescents with GHD. This open-label, u…

  4. 41.

    Ito K, Kawaguchi H, Shizume K, Hibi I · Nihon Jinzo Gakkai shi · 1995 · PMID 7731107

    We treated 90 pediatric patients with chronic renal failure with recombinant growth hormone (r-hGH) for 12 months to improve their growth retardation due to uremia. They were divided into two groups, non-dialyzed and dialyzed children. The dose of r-hGH was 0.5 or 1.0 IU/kg/week in dialyzed children. After 12 months of the treatment using r-hGH, growth velocity was significantly increased in any group of children. Growth velocity was stimulated to about twice as much as before treatment (that we…

  5. 42.

    Rosilio M, Carel JC, Ecosse E, Chaussainon JL · European journal of endocrinology · 2005 · PMID 15941922

    Human GH (hGH) treatment leads to catch-up growth in children with short stature born small for gestational age (SGA). However, long-term efficacy and safety results in this patient group remain scarce. The present study assessed the efficacy and safety of late childhood treatment with biosynthetic hGH (Humatrope) in a group of short children born SGA (height <-2 standard deviation scores (SDS)). Patients in this open-label, Phase III, multicenter study received a daily hGH dose of 0.067 mg/kg f…

  6. 43.

    Ito K, Kawaguchi H, Shizume K, Hibi I · Nihon Jinzo Gakkai shi · 1995 · PMID 7731108

    We treated 27 children with renal transplantation who showed growth failure due to deteriorated graft function and/or corticosteroids therapy with recombinant growth hormone (r-hGH) to improve their growth disturbance. The dose of rhGH was either 0.5 or 1.0 IU/kg/week. After 12 months treatment of r-hGH, growth velocity was significantly increased in both groups. Growth velocity was improved from 5.0 +/- 2.9 cm/year to 7.7 +/- 2.3 cm/year, P < 0.05, in 0.51U group and 3.7 +/- 2.4 cm/year to 6.3…

  7. 44.

    Bierich JR · Hormone research · 1989 · PMID 2699463

    Pituitary dwarfism with severe growth hormone deficiency (GHD) represents the classical indication for treatment by recombinant human growth hormone (hGH). With continuous GH replacement and early start of treatment, normal adult height can be achieved. During puberty the dosage of hGH administered should be increased. Numerous growth disorders do not coincide with major GHD as determined by provocative tests but only with diminished spontaneous hormone secretion. Typical examples are constituti…

  8. 45.

    Tai S, Tanaka T, Hasegawa T, Ozono K, et al. · Endocrine journal · 2013 · PMID 23001148

    This study assessed the effectiveness and safety of growth hormone (GH; Humatrope(®)) therapy in Japanese children with GH deficiency (GHD) or Turner syndrome (TS) enrolled in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). GeNeSIS is an open-label, multinational, multicenter, observational study conducted in 30 countries. In this interim report, there were 1129 GH treatment-naïve children with GHD, with a mean chronological age (± standard deviation) of 8.75…

  9. 46.

    Wilton P, Gunnarsson R · Acta paediatrica Scandinavica. Supplement · 1988 · PMID 3057810

    The efficacy of Genotropin (recombinant somatropin, KabiVitrum AB, Sweden) was analysed in 194 children with GH deficiency, comprising a combined series of four multicentre trials. The linear height velocity increased from 3.3 +/- 1.4 to 9.3 +/- 2.6 cm/year in 149 prepubertal children with 12 months' data available. In 18 pubertal children the pretreatment height velocity was 4.0 +/- 1.2, and increased to 8.4 +/- 1.7 cm/year during 12 months of treatment. There was a positive correlation between…

  10. 47.

    Goulet O, Dabbas-Tyan M, Talbotec C, Kapel N, et al. · JPEN. Journal of parenteral and enteral nutrition · 2010 · PMID 20852179

    This prospective study aimed to establish the effect of recombinant human growth hormone (rhGH) on intestinal function in children with short bowel syndrome (SBS). Eight children with neonatal SBS were included. All were dependent on parenteral nutrition (PN) for >3 years (range, 3.8-11.6 years), with PN providing >50% of recommended dietary allowance for age (range, 50%-65%). The subjects received rhGH (Humatrope) 0.13 mg/kg/d subcutaneously over a 12-week period. The follow-up was continued ov…

Trial Registrations (ClinicalTrials.gov)

29
  1. 48.

    NCT03015909 · Phase 4 · Completed · 2016

    Conditions: Short Stature, Idiopathic, Infant, Small for Gestational Age, Growth Hormone Deficiency (+2)

  2. 49.

    NCT01859949 · Phase 4 · Completed · 2002

    Conditions: Short Stature Born Small for Gestational Age (SGA)

  3. 50.

    NCT00080483 · Phase 2 · Completed · 2004

    Conditions: Hypopituitarism, Hypogonadism, Growth Hormone Deficiency

  4. 51.

    NCT02205450 · Completed · 2014

    Conditions: Prader-Willi Syndrome

  5. 52.

    NCT01512095 · Phase 1 · Withdrawn · 2013

    Conditions: Growth Disorder, Healthy

  6. 53.
  7. 54.

    NCT00294619 · Phase 3 · Completed · 2006

    Conditions: Pituitary Disorders, Adult Growth Hormone Deficiency

  8. 55.

    NCT00757393 · Phase 3 · Completed · 2008

    Conditions: Osteoporosis

  9. 56.

    NCT00490191 · Phase 4 · Completed · 1999

    Conditions: Hypopituitarism

  10. 57.
  11. 58.

    NCT00174278 · Phase 3 · Completed · 1997

    Conditions: Growth Hormone Deficiency, Growth Retardation

  12. 59.

    NCT00071240 · Phase 2 · Completed · 2002

    Conditions: HIV Infections

  13. 60.

    NCT00067860 · Phase 2 · Completed · 1996

    Conditions: Short Bowel Syndrome

  14. 61.

    NCT03309891 · Phase 2 · Completed · 2016

    Conditions: Growth Hormone Deficiency

  15. 62.

    NCT00813189 · Phase 3 · Completed · 2005

    Conditions: Chronic Disease, Glucocorticoid Therapy, Response to, Growth Retardation

  16. 63.

    NCT06900335 · Completed · 2025

    Conditions: Prader Willi Syndrome, Hyperphagia, Behavior Disorders

  17. 64.

    NCT02988687 · Completed · 2016

    Conditions: Adult-Onset Growth Hormone Deficiency

  18. 65.

    NCT00355784 · NA · Completed · 2005

    Conditions: Obesity

  19. 66.

    NCT05330325 · Phase 3 · Active Not Recruiting · 2022

    Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS

  20. 67.

    NCT02781727 · Phase 3 · Completed · 2016

    Conditions: Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases (+2)

  21. 68.

    NCT03972345 · Enrolling By Invitation · 2019

    Conditions: Growth Hormone Deficiency in Children, Born Small for Gestational Age

  22. 69.

    NCT03811535 · Phase 3 · Completed · 2019

    Conditions: Growth Hormone Deficiency in Children

  23. 70.
  24. 71.

    NCT04614337 · Phase 2 · Completed · 2020

    Conditions: Growth Hormone Deficiency

  25. 72.

    NCT07941518 · Not Yet Recruiting · 2026

    Conditions: Pediatric Growth Hormone Deficiency

  26. 73.

    NCT03878446 · Phase 2 · Active Not Recruiting · 2019

    Conditions: Short Stature Children Born Small for Gestational Age (SGA)

  27. 74.

    NCT05308927 · Enrolling By Invitation · 2022

    Conditions: Noonan Syndrome

  28. 75.

    NCT00663611 · Phase 1 · Completed · 2006

    Conditions: Healthy Volunteers

  29. 76.

    NCT06103513 · Phase 3 · Recruiting · 2023

    Conditions: Growth Disorders, Growth Failure, Growth Hormone Treatment (+1)

Reviews

20
  1. 77.

    Ranke MB · Frontiers in endocrinology · 2021 · PMID 34539573

    The syndrome of impaired GH secretion (GH deficiency) in childhood and adolescence had been identified at the end of the 19

  2. 78.

    Pawlikowska-Haddal A · Expert opinion on biological therapy · 2013 · PMID 23662811

    Growth hormone (GH) is indicated for therapy of growth hormone deficiency (GHD) in pediatric and adult patients. Introduction of recombinant human GH (rhGH) improved access to GH therapy. Norditropin [ somatropin (rDNA origin) injection] is rhGH, used for the replacement of endogenous GH in children and adults with GHD. The article reviews rhGH therapy in GHD indication with focus on Norditropin Nordiflex delivery system. The goals of therapy in children are to promote linear growth and restore…

  3. 79.

    Tanaka T · Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2022 · PMID 35002062

    In Japan, a pituitary-extracted human GH (phGH), Crescormon®, was approved for the treatment of pituitary dwarfism in 1975. The Study Group of Pituitary Dysfunction was organized by the Ministry of Health and Welfare (MHW) in 1973 and prepared the "Diagnostic Handbook: Pituitary Dwarfism" guidelines in 1974. Eligibility assessments for phGH treatment were conducted by the research group on pituitary dwarfism (later the Foundation for Growth Science [FGS] GH Treatment Eligibility Assessment Commi…

  4. 80.

    Höybye C, Thorén M · Treatments in endocrinology · 2004 · PMID 16026111

    Prader-Willi syndrome is a complex genetic disorder with a characteristic cognitive, behavioral, and endocrinologic phenotype. Obesity, partial growth hormone (GH) secretion, and hypogonadism are common. Results of several somatropin (GH therapy) studies in children with Prader-Willi syndrome have shown improvement in growth, body composition, physical strength, and agility. GH deficiency in adults without Prader-Willi syndrome is associated with abdominal obesity, insulin resistance, and an unf…

  5. 81.

    Giavoli C, Profka E, Rodari G, Lania A, et al. · Best practice & research. Clinical endocrinology & metabolism · 2017 · PMID 28477734

    The relationships between GH system and hypothalamic-pituitary-thyroid axis are complex and not yet fully understood. The reported effects of GH administration on thyroid status of GHD patients have been remarkably divergent. This review will focus on the main studies aimed to clarify the effects of GH on thyroid function, firstly going through the diagnosis of central hypothyroidism and its possible pitfalls, then elucidating the possible contexts in which GHD may develop and examining the prop…

  6. 82.

    Weise KL, Nahata MC · The Annals of pharmacotherapy · 2004 · PMID 15266039

    To review the indication, pharmacology, pharmacokinetics, efficacy, and adverse effects of recombinant human growth hormone in children with idiopathic short stature (ISS). A MEDLINE search (1966-December 2003) was performed using the key words human growth hormone, somatropin, Humatrope, normal children, somatrem, and idiopathic short stature. Food and Drug Administration Advisory Committee Meeting minutes were also reviewed. The data presented in this review were obtained from published litera…

  7. 83.

    Blethen SL, O'Brien F, Reinhart R · Pediatric endocrinology reviews : PER · 2005 · PMID 16456499

    The GHMonitor, introduced in 1998, monitors demographics and outcomes in children treated with Saizen (somatropin [recombinant hGH for injection]). Follow-up data are available on 697 patients. The proportion of male to female patients receiving growth hormone (GH) treatment was 67:33. Severity of the height deficit present at enrollment varied by diagnosis with patients with Turner syndrome being shortest [height standard deviation score (SDS)=-3.7+/-1.7] and those with organic GH deficiency th…

  8. 84.

    Tanaka T · Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2022 · PMID 36405437

    For the treatment of pituitary dwarfism (called pituitary short stature in 1987 and renamed as growth hormone deficiency [GHD] in 1993), pituitary-derived human growth hormone (phGH) was approved in 1975, and recombinant hGH (rhGH) was approved in 1988. Adult height in patients with isolated GH deficiency (IGHD) improved by 2000. However, this improvement was mainly due to the increase in height SDS at treatment initiation. Although the mean adult height in patients with idiopathic GHD has been…

  9. 85.

    Souza FM, Collett-Solberg PF · Arquivos brasileiros de endocrinologia e metabologia · 2011 · PMID 22218437

    Human growth hormone (hGH) replacement therapy has been widely available for clinical purposes for more than fifty years. Starting in 1958, hGH was obtained from cadaveric pituitaries, but in 1985 the association between hGH therapy and Creutzfeldt-Jakob disease was reported. In the same year, the use of recombinant hGH (rhGH) was approved. Side effects of rhGH replacement therapy in children and adolescents include rash and pain at injection site, transient fever, prepubertal gynecomastia, arth…

  10. 86.

    Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, et al. · Therapeutic advances in endocrinology and metabolism · 2025 · PMID 40832475

    Researchers looked at data from the largest and longest-running database of children with growth disorders who were treated with daily injections of a brand of growth

  11. 87.

    Peroni CN, Gout PW, Bartolini P · Current gene therapy · 2005 · PMID 16250890

    Treatment of growth hormone (GH) deficiency via parenteral administration of recombinant hGH has greatly benefited from recombinant DNA technology allowing production of practically unlimited amounts of the pure hormone. However, an alternative approach that may lead to correction of the clinical defect is presented by hGH gene transfer into somatic cells of the patient, either ex vivo or in vivo. This approach has not only the potential advantage of circumventing repetitive injections of the ho…

  12. 88.

    Kappelgaard AM, Hansen NÅ · Expert review of medical devices · 2013 · PMID 23560872

    Successful growth hormone (GH) therapy requires sustained treatment adherence, usually over long periods of time. However, adherence rates are often poor and this can lead to suboptimal clinical outcomes. Developments in GH injection devices aim to help improve adherence by making daily injections easier. Injection force is an important practical aspect for patients receiving daily GH injections, particularly for patients with small hands or reduced hand strength due to muscle weakness. Norditro…

  13. 89.

    He C, Wu M · Bioanalysis · 2009 · PMID 21083065

    Detection of doping with recombinant human growth hormone is one of the challenges for antidoping analysis. This review focuses on the most important relevant publications that provide insight into the laboratory measurement of human growth hormone (hGH), antibodies and standards, the isoform approach and the biomarker approach. The isoform approach monitors the changes of hGH molecular isoform composition in serum and was applied at the Olympic Games in Athens in 2004, Turin in 2006 and Beijing…

  14. 90.

    López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, et al. · Drug design, development and therapy · 2017 · PMID 28553079

    In 2006, the European Medicines Agency (EMA) approved Omnitrope

  15. 91.

    Ranke MB · Pediatric endocrinology reviews : PER · 2018 · PMID 30378783

    During the phase of using hGH extracted from pituitaries (pit hGH) - 1958-1985 - fundamental experience related to the diagnosis and treatment was accumulated. However, since recombinant hGH (rhGH) had become available diagnosis and treatment of GHD were conducted world-wide in a more standardized way. Treatment with rhGH was also accompanied by documentations in large international pharmaco-epidemiological surveys, which provided new insight. Despite of this development the treatment of childre…

  16. 92.

    Kappelgaard AM, Bojesen A, Skydsgaard K, Sjögren I, et al. · Hormone research · 2004 · PMID 15539807

    Growth hormone (GH) treatment is a successful medical therapy for children and adults with GH deficiency as well as for growth retardation due to chronic renal disease, Turner syndrome and in children born small for gestational age. For all of these conditions, treatment is long term and patients receive daily subcutaneous injections of GH for many years. Patient compliance is therefore of critical importance to ensure treatment benefit. One of the major factors influencing compliance is injecti…

  17. 93.

    Zucchini S · Current opinion in investigational drugs (London, England : 2000) · 2008 · PMID 18393106

    Human growth hormone (hGH) therapy has been used for the possible improvement of adult height in individuals with idiopathic short stature (ISS) for more than 20 years. However, given its heterogeneity, and the distinction between 'partial' or 'transient' GH deficiency, the exact definition of ISS is difficult. Since recombinant hGH became available, individuals with all types of GH deficiency have been extensively treated, often without the need for diagnostic justifications. On the other hand,…

  18. 94.

    Root AW, Root MJ · Current drug targets. Immune, endocrine and metabolic disorders · 2002 · PMID 12477295

    The regulation of the synthesis and secretion of human growth hormone (hGH), its biologic activity, and its therapeutic use are reviewed. Both the production and secretion of GH are stimulated by hypothalamic GH-releasing hormone (GHRH) and by the endogenous GH secretagogue (GHS) ghrelin, a product of the oxyntic cells located within the fundus of the stomach. Ghrelin and GHRH act synergistically to stimulate GH secretion when administered in vivo, but they act additively when incubated with som…

  19. 95.

    Borrás Pérez MV, Kriström B, Romer T, Walczak M, et al. · Drug design, development and therapy · 2017 · PMID 28553080

    Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope

  20. 96.

    Darendeliler F, Karagiannis G, Wilton P · Hormone research · 2007 · PMID 18174706

    Several uncommon adverse effects may be related to growth hormone (GH) treatment. Three potential side effects, headache, idiopathic intracranial hypertension (IIH) and slipped capital femoral epiphysis (SCFE), will be discussed. Data from 57,968 children in the KIGS (Pfizer International Growth Study database) were analyzed to determine the effects of recombinant human GH (Genotropin) on these side effects. The diagnostic groups were idiopathic GH deficiency (IGHD) (n = 27,690), congenital GHD…

Research Articles

114
  1. 97.

    Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, et al. · The Journal of clinical endocrinology and metabolism · 2022 · PMID 36102184

    The Kabi/Pfizer International Growth Database (KIGS) is a large, international database (1987-2012) of children treated with recombinant human growth hormone (rhGH) in real-world settings. This work aimed to evaluate the safety and efficacy of rhGH from the full KIGS cohort. Data were collected by investigators from children with growth disorders treated with rhGH (Genotropin [somatropin]; Pfizer). Safety was evaluated in all treated patients, and efficacy in those treated for 1 year or more. A…

  2. 98.

    Wilton P, Widlund L, Guilbaud O · Acta paediatrica Scandinavica. Supplement · 1987 · PMID 3481177

    The bioequivalence parameters, AUC, Cmax and Tmax were calculated from serum hGH concentration-time curves after subcutaneous injections of Genotropin (recombinant somatropin) and Somatonorm (somatrem) in a two-period crossover study in 11 healthy men aged 21-35 years. Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively. Criteria for bioequivalence were fulfilled for AUC. The bioavailability of Genotropin given subcutaneously was determined…

  3. 99.

    Tauber M, Diene G, Molinas C · Pediatric endocrinology reviews : PER · 2018 · PMID 30378786

    The European Marketing Authorization for recombinant human growth hormone (rhGH) in children with Prader-Willi syndrome was the first indication for metabolic and body composition effects in children. In the US it is indicated for short stature associated with PWS. Recombinant hGH is the first treatment for the PWS population and radically changed the care of these children by facilitating access to physicians who prescribe rhGH, mainly paediatric endocrinologists, and manage the organization of…

  4. 100.

    The Medical letter on drugs and therapeutics · 2022 · PMID 35134048

  5. 101.

    Esefeld M, Pastor A, de la Torre R, Barroso O, et al. · Journal of the Endocrine Society · 2021 · PMID 34765854

    Administration of human growth hormone (hGH) is prohibited in competitive sport and its detection in an athlete's sample triggers an adverse analytical finding. However, the biological processes that are modulated by recombinant hGH are not well characterized and associated blood serum proteins may constitute new biomarkers for hGH misuse. Thirty-five recreational athletes were enrolled in a study to investigate the time- and dose-dependent response of serum protein levels to recombinant hGH adm…

  6. 102.

    Tabatabaei-Malazy O, Mohajeri-Tehrani MR, Heshmat R, Taheri E, et al. · Journal of diabetes and metabolic disorders · 2014 · PMID 25648850

    Recombinant human growth hormone (rhGH) can increase the growth rate in growth hormone deficient children (GHD). In this randomized clinical trial, we compared the efficacy and side effects of an Iranian brand; Samtropin with Norditropin. The GHD children were randomly treated either with standard dose of Samtropin or Norditropin rhGH for one year. Upstanding height, height standard deviation score (HSDS), growth velocity (GV), serum levels of insulin like growth factor-1 (IGF-1), and bone age (…

  7. 103.

    Blair J, Warth K, Suvarna Y, Cappa M · Patient preference and adherence · 2021 · PMID 34584405

    This study investigated why some clinicians switched growth hormone (GH) brands in pediatric patients with GH-related disorders to Norditropin Clinicians (N=106) from the UK, France, Italy, and Japan who had switched at least one patient to Norditropin Since the start of COVID-19, 39-54% of the reported consultations were virtual (ie, via telephone or online means) in the UK, France, and Italy. Overall, 17% of patients seen by respondents in the survey were switched to a different GH brand; appr…

  8. 104.

    Fryklund L · Biologicals : journal of the International Association of Biological Standardization · 2006 · PMID 16330223

  9. 105.

    Mermans D, Nicolaus F, Baygin A, von Heijne G · FEBS letters · 2023 · PMID 36520514

    Human growth hormone (hGH) is a four-helix bundle protein of considerable pharmacological interest. Recombinant hGH is produced in bacteria, yet little is known about its folding during expression in Escherichia coli. We have studied the cotranslational folding of hGH using force profile analysis (FPA), both during in vitro translation in the absence and presence of the chaperone trigger factor (TF), and when expressed in E. coli. We find that the main folding transition starts before hGH is com…

  10. 106.

    Stanhope R, Buchanan C, Butler G, Costigan C, et al. · Journal of pediatric endocrinology & metabolism : JPEM · 2001 · PMID 11453523

    A new liquid formulation of hGH (Norditropin SimpleXx) has been developed to avoid the need for reconstitution before administration. In addition, the liquid GH formulation has been combined with an advanced pen delivery system, either with or without a needle auto-insertion mechanism. This study was designed to assess the acceptability of the new system compared with the patient's previous system. A total of 103 children with GH deficiency received a daily injection of Norditropin liquid GH for…

  11. 107.

    Phillip M, Abuzzahab MJ, Pietropoli A, Ferran JM, et al. · Journal of the Endocrine Society · 2025 · PMID 40980545

    GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited. To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH). This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who in…

  12. 108.

    Rohrer TR, Kotnik P, Miller BS, Kelepouris N, et al. · Endocrine connections · 2025 · PMID 40919719

    Limited data are available on the growth response to growth hormone (GH) treatment in very young children with GH deficiency (GHD). In the present analysis, we compared clinical outcomes after GH treatment in children with GHD aged <2 and ≥2 years at the start of GH treatment. We analysed pooled data from two observational studies of paediatric patients who received Norditropin® treatment: NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905). Patients with GHD, who remained pre-puber…

  13. 109.

    Tauber M, Jaquet D, Jesuran-Perelroizen M, Petrus M, et al. · Patient preference and adherence · 2013 · PMID 23737664

    BACKGROUNDAIM: In growth disorders, ensuring long-term growth hormone therapy (GHT) remains a challenge that might compromise the clinical outcome. Consequently, strategies aiming at alleviating the burden of daily injection might improve the treatment benefit. The study reported here was performed to assess the ease of use of Norditropin NordiFlex(®) (Novo Nordisk, Princeton, NJ, USA) compared with that of the devices previously used in children treated with GHT with recombinant somatropin. Thi…

  14. 110.

    Iyoda K, Moriwake T, Seino Y, Niimi H · Hormone research · 1999 · PMID 10592454

    Human growth hormone (hGH) is an essential therapeutic drug for the treatment of GH deficiency. The development of recombinant GH using a pen injection system has enabled easy and safe treatment of GH-deficient patients; however, the process of dissolving hGH in the powder form is complicated and dangerous. In this study, we investigated the usefulness of a newly developed liquid form of hGH (Norditropin((R)) SimpleXx(TM)) in the treatment of 51 patients with GH deficiency. Fifteen previously un…

  15. 111.

    Fu J, Cheng X, Højby M, Gong C, et al. · Hormone research in paediatrics · 2025 · PMID 40324364

    REAL6 is a randomized, multi-centre, open-labelled, active-controlled parallel group phase 3 trial (NCT04970654) investigating once-weekly somapacitan, a reversible albumin-binding growth hormone (GH) derivative, in Chinese children with GH deficiency (GHD). 110 treatment-naïve patients were randomized 2:1 to somapacitan (0.16 mg/kg/week) or daily GH (Norditropin®; 0.034 mg/kg/day) for 52 weeks. Annualized height velocity (HV; cm/year) at week 52 was the primary measurement. Additional assessmen…

  16. 112.

    Carmichael JD, Kargi AY, Dichtel L, Kelepouris N, et al. · Journal of the Endocrine Society · 2025 · PMID 40078421

    Adult growth hormone deficiency (AGHD) is a rare disease with both physiological and psychological effects for untreated patients. AGHD symptoms can improve over time with GH treatment. Here we have analyzed the long-term effectiveness and safety of short-acting GH replacement therapy (GHRT) in treatment naïve and nonnaïve patients with AGHD using real-world data from the NordiNet® International Outcome Study and American Norditropin® Studies: Web Enabled Research Program. Outcomes were compared…

  17. 113.
  18. 114.

    Hepner F, Csaszar E, Roitinger E, Pollak A, et al. · Proteomics · 2006 · PMID 16372270

    Recombinant human growth hormone (rhGH) is used for the treatment of several disorders. Structural integrity of rhGH is of critical importance for its clinical use and modifications thereof may act as markers in situations such as rhGH doping, as illegal rhGH-abuse in sports is of increasing interest. In the current study we investigated homogeneity of Norditropin, a recombinant human growth hormone frequently used in medicine, expressed in E. coli, strain MC1061. The most recent proteomics tech…

  19. 115.

    Wada M, Uchida H, Ikeda M, Tsunekawa B, et al. · Molecular endocrinology (Baltimore, Md.) · 1998 · PMID 9440818

    In spite of recent advance in understanding of the stoichiometry of 22-kDa human GH (22K-hGH) with cell surface hGH receptor (hGHR) and hGH-binding protein (hGH-BP) circulating in human plasma, that of 20-kDa hGH (20K-hGH) is poorly understood. To clarify this, mouse pro-B Ba/F3 cells stably expressing the full-length hGHR (Ba/F3-hGHR) and both recombinant and native hGH-BP were used in this study. Cell proliferation assay revealed that the two hGH isoforms increased Ba/F3-hGHR cells to the same…

  20. 116.

    Kawashige M, Sendo T, Otsubo K, Aoyama T, et al. · Biological & pharmaceutical bulletin · 1995 · PMID 8787812

    The quality of three commercial injections (Genotropin, Humatrope and Norditropin) of lyophilized recombinant human growth hormone (r-hGH) was evaluated in tests by visual inspection, high-performance gel permeation chromatography, polyacrylamide gel electrophoresis, scanning electron microscopy and energy dispersion X-ray microanalysis. The influence of the reconstitution method on gel formation was examined as follows: rapid injection of the diluting solution into a vial against the wall, slow…

  21. 117.

    Bidlingmaier M, Wu Z, Strasburger CJ · Journal of endocrinological investigation · 2003 · PMID 14964447

    Human hGH is listed as a prohibited class E substance by the International Olympic Committee (IOC), and its use is considered as doping. However, until today the likelihood of being punished for using recombinant hGH is very limited: once injected, it is believed to be undetectable by laboratories. No official test is implemented in the doping control procedures, and the only situation when athletes were found guilty of doping with hGH arose from actions of customs officers or policemen arrestin…

  22. 118.

    Bayol A, Bristow A, Charton E, Girard M, et al. · Pharmeuropa bio · 2004 · PMID 15659284

    Human Growth hormone (hGH, somatotrophin) is a 22 kDa, 191 amino-acid single chain protein produced by somatroph cells of the anterior pituitary gland. It is the major physiological regulator of growth, and deficiencies in growth hormone levels have long been recognized as the underlying cause of growth disorders (dwarfism). The ability of exogenous hGH to restore normal rates of growth in both human and animal models of growth retardation has long been recognized and the use of hGH in therapy g…

  23. 119.

    Weber MM, Gordon MB, Höybye C, Jørgensen JOL, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2020 · PMID 31972476

    This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0-12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905). In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of th…

  24. 120.

    Harding PA, Wang X, Okada S, Chen WY, et al. · The Journal of biological chemistry · 1996 · PMID 8636090

    It has previously been shown that a human growth hormone (hGH) analog, hGH-G120R, acts as a GH antagonist (Chen, W. Y., Wight, D. C. , Wagner, T. E., and Kopchick, J. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5061-5065; Chen, W. Y., White, M. E., Wagner, T. E., and Kopchick, J. J. (1991) Endocrinology 129, 1402-1408; Chen, W. Y., Chen, N-Y., Yun, J., Wang, X. Z., Wagner, T. E., and Kopchick, J. J. (1994) J. Biol. Chem. 269, 15892-15897). In this study, we report the ability of hGH and hGH-G1…

  25. 121.

    Kadono-Okuda K, Yamamoto M, Higashino Y, Taniai K, et al. · Biochemical and biophysical research communications · 1995 · PMID 7646491

    To express the cDNA encoding human growth hormone (hGH) in larvae of Bombyx mori, B. mori nuclear polyhedrosis virus (BmNPV) was employed as an expression vector. For the construction of the recombinant virus, the hGH cDNA was inserted into the downstream of the strong polyhedrin promoter to achieve a high level expression. Immunoblot analysis revealed that the virus-mediated hGH was synthesized in the larvae and secreted into the hemolymph. The yield of the recombinant hGH synthesized in the la…

  26. 122.

    Rigi G, Rostami A, Ghomi H, Ahmadian G, et al. · BMC biotechnology · 2021 · PMID 34399745

    Human Growth Hormone (hGH) is a glycoprotein released from the pituitary gland. Due to the wide range of effects in humans, any disruption in hGH secretion could have serious consequences. This highlights the clinical importance of hGH production in the treatment of different diseases associated with a deficiency of this hormone. The production of recombinant mature hormone in suitable hosts and secretion of this therapeutic protein into the extracellular space can be considered as one of the be…

  27. 123.

    Backeljauw P, Blair JC, Ferran JM, Kelepouris N, et al. · The Journal of clinical endocrinology and metabolism · 2023 · PMID 36947589

    Despite having normal growth hormone (GH) secretion, individuals with Turner syndrome (TS) have short stature. Treatment with recombinant human GH is recommended for TS girls with short stature. This work aimed to evaluate the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS. Secondary analysis was conducted of Norditropin data from 2 non-interventional studies: NordiNet® IOS (NCT00960128) and the ANSWER program (NCT01009905)…

  28. 124.

    Lee SY, Han JH, Lee EK, Kim YK, et al. · PloS one · 2020 · PMID 32735629

    This study aimed to establish and reproduce transgenic pigs expressing human growth hormone (hGH) in their milk. We also aimed to purify hGH from the milk, to characterize the purified protein, and to assess the potential of our model for mass production of therapeutic proteins using transgenic techniques. Using ~15.5 L transgenic pig milk, we obtained proteins with ≥ 99% purity after three pre-treatments and five column chromatography steps. To confirm the biosimilarity of our milk-derived puri…

  29. 125.

    Keshavarz R, Babaeipour V, Mohammadpour-Aghdam M, Deldar AA · Biotechnology and applied biochemistry · 2021 · PMID 32092174

    Overexpression of insoluble human growth hormone (hGH) in cytoplasm was achieved by E. coli Rosetta-gami B(DE3) [pET21a (+)-hGH]). For overexpression of hGH, effects of eight factors including temperature, type and concentration of carbon source, IPTG and MgSO

  30. 126.

    Hepner F, Cszasar E, Roitinger E, Lubec G · Proteome science · 2005 · PMID 15707495

    BACKGROUND: The structural integrity of recombinant proteins is of critical importance to their application as clinical treatments. Recombinant growth hormone preparations have been examined by several methodologies. In this study recombinant human growth hormone (rhGH; Genotropin(R)), expressed in E. coli K12, was structurally analyzed by two-dimensional gel electrophoresis and MALDI-TOF-TOF, LC-MS and LC-MS/ MS sequencing of the resolved peptides. RESULTS: Electrospray LC-MS analysis revealed…

  31. 127.

    Bazalo GR, Joshi AV, Germak J · Managed care (Langhorne, Pa.) · 2007 · PMID 17969748

    We assessed the economic impact to the United States payer of recombinant human growth hormone (rhGH) utilization, comparing the relative dosage efficiency of marketed pen-based and vial-based products in a pediatric and in an adult population. A budgetary impact model calculated drug costs based on product waste and cost. Waste was the difference between prescribed dose, based on patient weight, and actual delivered dose, based on dosing increments and maximum deliverable dose for pens and a fi…

  32. 128.

    Dahlgren J, Albertsson-Wikland K · Frontiers in endocrinology · 2021 · PMID 34858328

    Despite different genetic background, Noonan syndrome (NS) shares similar phenotype features to Turner syndrome (TS) such as short stature, webbed neck and congenital heart defects. TS is an entity with decreased growth hormone (GH) responsiveness. Whether this is found in NS is debated. Data were retrieved from combined intervention studies including 25 children diagnosed with NS, 40 diagnosed with TS, and 45 control children (all prepubertal). NS-children and TS-girls were rhGH treated after i…

  33. 129.

    Zhou ZR, Huang W, Liu KJ, Lin FL, et al. · Protein and peptide letters · 2021 · PMID 33172365

    Human growth hormone (hGH) is the first recombinant protein approved for the treatment of human growth hormone deficiency. However, expression in inclusion bodies and low expression levels are enormous challenges for heterologous expression of hGH in Escherichia coli. To increase the soluble expression of recombinant hGH with correct folding in E. coli. We constructed a new recombinant expression plasmid containing the coding sequence of the outer membrane protein A (ompA3) which was used for th…

  34. 130.

    Gordon MB, Levy RA, Gut R, Germak J · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016 · PMID 26574788

    Adult growth hormone deficiency (AGHD) results in physiologic impairments that may reduce quality of life and negatively impact body composition. AGHD can be treated with recombinant human growth hormone (GH). This study analyzes AGHD patients enrolled in the American Norditropin(®) Web-Enabled-Research (ANSWER) Program/NovoNet, a U.S. observational noninterventional study of patients treated with Norditropin(®) (somatropin [recombinant DNA origin] injection) at the discretion of their physician…

  35. 131.

    Gertler A, Shamay A, Cohen N, Ashkenazi A, et al. · Endocrinology · 1986 · PMID 2417826

    A recombinant analog of human GH (hGH) lacking 13 amino acids at the amino-terminus (Met14hGH) inhibited the hGH- or ovine PRL (oPRL)-stimulated proliferation of Nb2 lymphoma cells and bovine PRL-stimulated fat synthesis and alpha-lactalbumin secretion in explants from bovine lactating mammary gland. The inhibition was competitive in nature, and in Nb2 cells could be abolished by an excess of hGH or oPRL. Inhibition of oPRL-stimulated proliferation of Nb2 cells by Met14hGH could also be specific…

  36. 132.

    Ishii H, Shimatsu A, Nishinaga H, Murai O, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017 · PMID 28923784

    Improvement of quality of life (QOL) by growth hormone (GH) therapy was not demonstrated in Japanese adult growth hormone deficiency (AGHD) patients by either the QOL Assessment of Growth Hormone Deficiency in Adults or the Questions on Life Satisfaction-Hypopituitarism, which are widely used to evaluate QOL in Western AGHD patients. We therefore evaluated QOL in Japanese AGHD patients receiving recombinant GH, Norditropin® (Novo Nordisk A/S, Denmark), using the newly developed Adult Hypopituita…

  37. 133.

    Ghasemi F, Zare H, Zomorodipour A, Shirzeyli MH, et al. · Archives of microbiology · 2022 · PMID 36001178

    The secretion efficiency of a heterologous protein in E. coli is mainly dictated by the N-terminal signal peptide fused to the desired protein. In this study, we aimed to select and introduce mutations into the - 1, - 2 and - 3 positions of the gIII signal peptide (originated from filamentous phage fd Gene III) fused to the N-terminus of the human growth hormone (hGH), and study its effect on the secretion efficiency of the recombinant hGH into the periplasmic space of E. coli Top10. Bioinformat…

  38. 134.

    Baumann G, Vance ML, Shaw MA, Thorner MO · The Journal of clinical endocrinology and metabolism · 1990 · PMID 2380341

    We have previously shown that a substantial part of human GH is complexed with GH-binding proteins (BPs) when GH is incubated with plasma in vitro. The proportion of GH bound in vivo, however, is unknown and may differ because of factors that cannot be assessed in vitro, such as binding to tissue receptors, distribution of GH outside the vascular compartment, and fluctuating GH and possibly BP levels. Accordingly, we studied the plasma transport characteristics of GH in vivo in six normal men. M…

  39. 135.

    Adachi M · Journal of pediatric endocrinology & metabolism : JPEM · 2013 · PMID 23843576

    To assess the user-friendliness of the Norditropin FlexPro (Novo Nordisk A/S, Bagsvaerd, Denmark), a newly developed growth hormone (GH) injection pen. This study consisted of a single-center, single-arm, open-label, questionnaire based survey of patients undergoing GH treatment for diverse indications who were scheduled to switch from the formerly used device Norditropin NordiFlex (Novo Nordisk A/S) to the FlexPro and evaluate each device's usability. A total of 82 patients participated in the…

  40. 136.

    Yuen KC, Amin R · Patient preference and adherence · 2011 · PMID 21448295

    Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently efficacy outcomes. To enhance potential treatment adherence, improved ease of use of growth hormone delivery devices and long-acting growth hormone formulations are now being developed. Flexpro(®), approve…

  41. 137.

    Sjöblom K, Albertsson-Wikland K, Bengtsson BA, Johannsson G, et al. · Acta paediatrica (Oslo, Norway : 1992). Supplement · 1995 · PMID 8563072

    The aim of this study was to evaluate patients' perception and acceptance of a new multi-dose injection device (Genotropin Pen) for recombinant growth hormone (GH) supplied in a two-chamber cartridge. The pen is combined with a very thin needle (B-D Microfine + (29 G) and meets future demands when dosing of GH will be changed from International Units (IU) to milligrams (mg). A total of 39 children receiving GH treatment (East Hospital, Gothenburg and St Bartholomew's Hospital, London), aged betw…

  42. 138.

    Cunha NB, Murad AM, Cipriano TM, Araújo AC, et al. · Transgenic research · 2011 · PMID 21069461

    We produced human growth hormone (hGH), a protein that stimulates growth and cell reproduction, in genetically engineered soybean [Glycine max (L.) Merrill] seeds. Utilising the alpha prime (α') subunit of β-conglycinin tissue-specific promoter from soybean and the α-Coixin signal peptide from Coix lacryma-jobi, we obtained transgenic soybean lines that expressed the mature form of hGH in their seeds. Expression levels of bioactive hGH up to 2.9% of the total soluble seed protein content (corres…

  43. 139.

    Kuo HF, Liu PC, Shih KC, Lee TS, et al. · Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui · 1992 · PMID 1626447

    Five prepubertal children with previously untreated growth hormone deficiency were enrolled in this trial and treated with authentic recombinant human growth hormone hGH, 0.1 IU/Kg/day, subcutaneously, for one year. All of the children markedly increased their growth rate; the height velocity increased from 3.4 +/- 0.7 cm/yr to 11.3 +/- 2.0 cm/yr during one year's treatment. The height-standard deviation score for chronological age increased from -4.03 +/- 0.52 to -2.70 +/- 0.68. The bone age in…

  44. 140.

    Johannsson G, Touraine P, Feldt-Rasmussen U, Pico A, et al. · The Journal of clinical endocrinology and metabolism · 2022 · PMID 35368070

    Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed. We aimed to evaluate the safety of GH in the full KIMS (Pfizer International Metabolic Database) cohort. The worldwide, observational KIMS study included adults and adolescents with confirmed GHD. Patients were treated with GH (Genotropin [somatropin]; Pfizer, NY) and followed through routine clinical practice. Adverse events (AEs) and clinical characteristics (eg, lipid profile, glucose) w…

  45. 141.

    Borson-Chazot F, Chabre O, Salenave S, Klein M, et al. · Annales d'endocrinologie · 2021 · PMID 33290752

    Using real-world data from patients with growth hormone deficiency (GHD), we evaluated whether clinical practice in France adheres to international guidelines regarding somatropin dose adjustment, and assessed the long-term effectiveness and safety of somatropin. Data were obtained from a national prospective systematic longitudinal routine follow-up programme of naive/non-naive adults with childhood-onset (CO) or adult-onset (AO) GHD treated with Norditropin® (Novo Nordisk A/S). Between 2003 an…

  46. 142.

    Lee PA, Ross J, Germak JA, Gut R · International journal of pediatric endocrinology · 2012 · PMID 22682146

    Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been approved by the United States Food and Drug Administration for short stature in children with NS. The objective of this analysis was to assess the height standard deviation score (HSDS) and change in HSDS (ΔHSDS) for up to 4 years (Y4) of GH therapy in children with NS. The American Norditropin Studies: Web-Enab…

  47. 143.

    Cardoso AI, Llera AS, Iacono RF, Domené HM, et al. · Acta endocrinologica · 1993 · PMID 8351954

    The existence of homologous anti-human growth hormone (anti-hGH) and heterologous anti-bovine growth hormone (anti-bGH) humoral immune responses in hypopituitary patients under hGH therapy has been reported previously. In order to study the influence of the hormone source, both responses were compared by radiobinding assays performed with [125I]hGH or [125I]bGH as tracers. Fifty-seven hypopituitary patients treated with extractive hGH, recombinant methionyl hGH or authentic recombinant hGH were…

  48. 144.

    Ozdamar TH, Sentürk B, Yilmaz OD, Calik G, et al. · Biotechnology progress · 2009 · PMID 19224557

    We demonstrate for the first time, an expression system mimicking serine alkaline protease synthesis and secretion, producing native form of human growth hormone (hGH) from Bacillus subtilis. A hybrid-gene of two DNA fragments, i.e., signal (pre-) DNA sequence of B. licheniformis serine alkaline protease gene (subC) and cDNA encoding hGH, were cloned into pMK4 and expressed under deg-promoter in B. subtilis. Recombinant-hGH (rhGH) produced by B. subtilis carrying pMK4::pre(subC)::hGH was secrete…

  49. 145.

    Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard AM · Clinical therapeutics · 2009 · PMID 20110030

    Recombinant human growth hormone (GH) is used for the treatment of several conditions associated with growth retardation and metabolic dysfunction. These patients are typically diagnosed and treated from childhood, and treatment adherence in children might be problematic. To potentially improve treatment adherence in children who self-inject GH, it is important that devices for the administration of GH are simple to learn to use, simple to use, and well accepted by patients and their parents or…

  50. 146.

    Biller BMK, Höybye C, Ferran JM, Kelepouris N, et al. · Journal of the Endocrine Society · 2023 · PMID 37197408

    Effectiveness and safety data on GH replacement therapy (GHRT) in older adults with adult GH deficiency (AGHD) are limited. To compare GHRT safety and clinical outcomes in older (≥60 years and, for some outcomes, ≥75 years) and middle-aged (35-<60 years) patients with AGHD. Ten-year follow-up, real-world data from 2 large noninterventional studies-NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program-were analyzed. GH-naïve and n…

  51. 147.

    Bolin K, Sandin R, Koltowska-Häggström M, Loftus J, et al. · Cost effectiveness and resource allocation : C/E · 2013 · PMID 24079522

    To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting. A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin®. Al…

  52. 148.

    Bosch J, Luchini A, Pichini S, Tamburro D, et al. · Journal of pharmaceutical and biomedical analysis · 2013 · PMID 23954438

    Successful application clinical-grade human growth hormone (hGH) immunoassays to the discovery of illegal doping cases has been rare. Indeed, the preferred biological matrix in doping control is urine, where the estimated baseline concentration of hGH falls well below the linear range and sensitivity threshold of all commercially available immunoassays, including hGH isoform differential immunoassays which can discriminate pituitary endogenous hGH from recombinant hGH. We employed hydrogel nanop…

  53. 149.

    Lin Z, Amesso Ndengue PP, Jing Y, Zhao L, et al. · Protein expression and purification · 2021 · PMID 34520839

    Human growth hormone (hGH) plays an important role in growth control, growth promotion, cell development, and regulation of numerous metabolic pathways in the human body and has been approved by the U.S. FDA for the treatment of several human dysfunctions. Over-expression of recombinant hGH (rhGH) affords a misfolded form in cytoplasm of Escherichia coli, and the refolding step required to obtain active rhGH greatly affects its production costs. Herein, the cleavable self-aggregating tag (cSAT)…

  54. 150.

    Lee CH, Woo JH, Cho KK, Kang SH, et al. · Biotechnology and applied biochemistry · 2007 · PMID 17067288

    The major obstacle for oral delivery of administered therapeutic proteins is malabsorption in the intestine. This malabsorption could be overcome by induction of neonatal FcRn [Fc (CH2 and CH3 domains of human IgG1 antibody) receptor]-mediated transcytosis in the intestine using recombinant fusion of CH2 and CH3 moieties of human IgG to a therapeutic protein. To this end we developed recombinant hGH (human growth hormone) fused to the N-terminus of Fc moieties [CH2-CH3 or h (hinge)-CH2-CH3] from…

  55. 151.

    Cherbonnier C, Déas O, Carvalho G, Vassal G, et al. · British journal of cancer · 2003 · PMID 12966434

    In addition to its primary role as growth factor, human growth hormone (hGH) can also participate in cell survival, as already documented by its protective effect on human monocytes or human promyelocytic leukaemia U937 cells exposed to a Fas-mediated cell death signal. However, despite similarities in the molecular events following Fas and TNF-alpha receptor engagement, we report that U937 cells, genetically engineered to constitutively produce hGH, were made more sensitive to TNF-alpha-induced…

  56. 152.

    Laron Z · Pediatric endocrinology reviews : PER · 2018 · PMID 30378778

    The first patient treated with cadaveric pituitary GH (hGH) was reported in 1958. Subsequently, collection of cadaveric pituitaries started in many countries and several centers extracted the hormone using one of two methods: a. Acetone preservation and extraction with hot glacial acetic acid (Rabin method) b. Collection in distilled water, freezing and extraction on columns yielding several pituitary hormones including hGH (Wilhelmi method). The purified extracts of hGH were found to have metab…

  57. 153.

    Sakal E, Tchelet A, Uchida E, Shimokawa S, et al. · Molecular and cellular endocrinology · 1993 · PMID 8143895

    Four analogues of human growth hormone (hGH) mutated by site-directed mutagenesis at the 54-74 loop-Met-hGH(P59A), Met-hGH(P61A), Met-hGH(P59A,P61A) and Met-hGH(Des 62-67) were analyzed for: (1) their biological activity mediated through lactogenic receptors using rat lymphoma Nb2-11C cell proliferation and mouse mammary gland HC-11 cell beta-casein synthesis bioassays and (2) their ability to interact with recombinant hGH binding protein (hGHBP). The analogues Met-hGH(P59A), Met-hGH(P61A) and M…

  58. 154.

    Strasburger CJ, Kostyo J, Vogel T, Barnard GJ, et al. · Endocrinology · 1989 · PMID 2465140

    The antigenic epitopes of human GH (hGH) have been investigated using monoclonal antibodies (Mabs) to hGH. A panel of 12 Mabs was incorporated into two-site binding assays in order to investigate the antigenic surface of hGH. Nine reaction patterns were observed. The Mabs were further characterized in terms of their cross-reactivity with human placental lactogen, human PRL, with recombinant hGH molecules (MetLeu8hGH, Met14hGH), and with fragments derived from enzymatic or chemical digestion of h…

  59. 155.

    Fairhall KM, Carmignac DF, Robinson IC · Endocrinology · 1992 · PMID 1396340

    GH binding proteins (GHBPs) are present in the blood of several species and by complexing with circulating GH may alter its clearance and distribution. The actions of human GHBP (hGHBP) have hitherto been studied indirectly via their effects on the clearance of hGH. In the present experiments, recombinant preparations of hGHBP and a shorter variant lacking exon 3 (delta 3hGHBP) were tested in vivo, either alone or after preincubation with recombinant hGH, recombinant 20K methionyl-hGH, or rat GH…

  60. 156.

    Wojtowicz-Krawiec A, Sokolowska I, Smorawinska M, Chojnacka-Puchta L, et al. · Microbial cell factories · 2014 · PMID 25158991

    Numerous bacterial human growth hormone (hGH) expression methods under conventional fermentation and induction conditions have been described. Despite significant progress made in this area over the past several years, production of recombinant hGH by using cellular expression systems still requires further optimization. Fusion of the ubiquitin (Ub) tag to the hGH protein allowed to increase of the overall efficiency of the biosynthesis and improve the protein stability. Ub is a protein composed…

  61. 157.

    Mullis PE, Brickell PM · Clinical endocrinology · 1992 · PMID 1424197

    Familial isolated growth hormone deficiency (IGHD) type IA is characterized by a complete absence of human growth hormone (hGH) resulting in most cases from either a 6.7 or 7.7 kb deletion of DNA containing the hGH-1 gene. These patients have a strong initial anabolic response to exogenous recombinant hGH (r-hGH) therapy, frequently associated with the development of immune intolerance to r-hGH which causes an arrest of response to r-hGH replacement. This disorder is inherited as an autosomal re…

  62. 158.

    Haddad H, Mroueh M, Faour WH, Daher C · Endocrine research · 2014 · PMID 23772680

    Impairments in neuroendocrine regulation of food intake and postprandial satiety are leading causes to obesity. Ghrelin peptide is a GI hormone known to increase food intake partly through induction of growth hormone. The regulation of ghrelin production is still unknown. The aim of the current study is to investigate the influence of growth hormone (Genotropin) treatment on active ghrelin levels in plasma, stomach, pancreas and kidney in rats. Male Sprague-Dawley rats, randomly allocated into c…

  63. 159.

    Kriström B, Ankarberg-Lindgren C, Barrenäs ML, Nilsson KO, et al. · Frontiers in endocrinology · 2023 · PMID 37529614

    To study the impact of GH dose and age at GH start in girls with Turner syndrome (TS), aiming for normal height and age at pubertal onset (PO) and at adult height (AH). However, age at diagnosis will limit treatment possibilities. National multicenter investigator-initiated studies (TNR 87-052-01 and TNR 88-072) in girls with TS, age 3-16 years at GH start during year 1987-1998, with AH in 2003-2011. Of the 144 prepubertal girls with TS, 132 girls were followed to AH (intention to treat), while…

  64. 160.

    Höybye C, Sävendahl L, Christesen HT, Lee P, et al. · Clinical epidemiology · 2013 · PMID 23658497

    Randomized controlled trials have shown that growth hormone (GH) therapy has effects on growth, metabolism, and body composition. GH therapy is prescribed for children with growth failure and adults with GH deficiency. Carefully conducted observational study of GH treatment affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables affecting those outcomes, in patients receiving GH therapy in routine clinical practice. The NordiNet® International Outcom…

  65. 161.

    Biller BMK, Höybye C, Carroll P, Gordon MB, et al. · Pituitary · 2021 · PMID 33709288

    Data on the safety of growth hormone (GH) replacement therapy during pregnancy are limited. We report a combined analysis of data from pregnant women treated with GH while enrolled in two non-interventional, multicenter studies: NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program. Pregnancy data were pooled from NordiNet® IOS and the ANSWER Program. Data were collected during routine clinic visits by participating physicians us…

  66. 162.

    Carón RW, Jahn GA, Deis RP · The Journal of endocrinology · 1994 · PMID 7964304

    We studied the capacity of different GH preparations, natural human (h)GH, recombinant hGH (rhGH), rat (r)GH, ovine (o)GH, bovine (b)GH and porcine (p)GH, and ovine prolactin (oPRL), to stimulate lactogenesis in ovario-hysterectomized pregnant rats or intact lactating rats treated with bromocriptine (BC). Ovariohysterectomy (OVX-HYS) performed at 0800 h on day 19 of pregnancy induced lactogenesis, i.e. increases in mammary casein and lactose and positive response to the oxytocin test, 28 h later…

  67. 163.

    Kim ES, Jang DS, Yang SY, Lee MN, et al. · Nanoscale · 2013 · PMID 23546513

    Nanotechnology has been applied to the development of more effective and compatible drug delivery systems for therapeutic proteins. Human growth hormone (hGH) was fused with a hybrid Fc fragment containing partial Fc domains of human IgD and IgG4 to produce a long-acting fusion protein. The fusion protein, hGH-hyFc, resulted in the increase of the hydrodynamic diameter (ca. 11 nm) compared with the diameter (ca. 5 nm) of the recombinant hGH. A diblock copolymer membrane with nanopores (average d…

  68. 164.

    Khadilkar V, Ekbote V, Khadilkar A, Maheshwari A · Indian journal of endocrinology and metabolism · 2018 · PMID 30148102

    To study efficacy and safety of use of biosimilar growth hormone (GH) in Indian children with growth disorders. We studied 322 children (May 2012-2017) with growth disorders including growth hormone deficiency (GHD), multiple pituitary hormone deficiency (MPHD, idiopathic short stature (ISS), small for gestational age (SGA), and Turner syndrome (TS). Children were treated either with innovator molecule (Norditropin) or biosimilar GH (Headon) with standard dosage protocol for 1 year. Height and w…

  69. 165.

    Drent ML, Jakobsdottir S, van Wijk JAE, Oostdijk W, et al. · Clinical drug investigation · 2002 · PMID 29492857

    Human growth hormone (GH) is well established as a treatment for growth hormone deficiency. Recently, a new liquid GH formulation (Norditropin SimpleXx®) has become available that does not require reconstitution before subcutaneous self-administration with a new delivery system (NordiPen™) and an optional auto-injector (NordiPenmate™). In this study the acceptability and tolerability of and compliance with the liquid formulation were investigated DESIGN AND PATIENTS: An open 6-week multicentre t…

  70. 166.

    Johnson OL, Cleland JL, Lee HJ, Charnis M, et al. · Nature medicine · 1996 · PMID 8673926

    An injectable sustained-release form of human growth hormone (hGH) was developed by stabilizing and encapsulating the protein, without altering its integrity, into biodegradable microspheres using a novel cryogenic process. A single injection of microspheres in monkeys resulted in elevated serum levels of recombinant hGH (rhGH) for more than one month. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-3, both of which are induced by hGH, were also elevated for four weeks by the…

  71. 167.

    Yokoya S, Hasegawa T, Ozono K, Tanaka H, et al. · Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2017 · PMID 29026272

    The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope

  72. 168.

    Kunert R, Steinfellner W, Altmann F, Wallner J, et al. · Applied microbiology and biotechnology · 2009 · PMID 19396439

    Protein-free media are gaining more and more interest in mammalian cell culture technology. However, the range of commercially available protein-free media is wide, but lack of serum causes the lack of various substances (Keenan et al. in Cytotechnology, 50(1-3):49-56, 2006) which must be substituted case by case. Details on the composition of protein-free media are often unavailable or inaccessible in some cases, and as a consequence, there is an obvious need for testing procedures in order to…

  73. 169.

    Zamani M, Nezafat N, Ghasemi Y · Avicenna journal of medical biotechnology · 2016 · PMID 27920886

    In the recent years, there has been an increasing interest in secretory production of recombinant proteins, due to its various advantages compared with intracellular expression. Signal peptides play a critical role in prosperous secretion of recombinant proteins. Accordingly, different signal peptides have been assessed for their ability to produce secretory proteins by trial-and-error experiments. The aim of this study was to evaluate the effect of L-asparaginase II signal peptide on the recomb…

  74. 170.

    Chen JV, Miller BS, Kelepouris N, Kennedy C, Wayser GR, Mason B, Yuen KCJ. · 2026 · PMID 41783509

    <h4>Context</h4>Once-weekly long-acting growth hormone (GH) analogue (LA-GHA) treatments offer an alternative to once-daily GH injections for the treatment of children and adults with GH deficiency (GHD). With these new LA-GHA options, it is important to understand patients' and caregivers' treatment preferences.<h4>Objective</h4>This work aimed to understand the injection/device attributes important to patients with GHD and caregivers when choosing LA-GHA treatment options.<h4>Methods</h4>In th…

  75. 171.

    2006 · PMID 30000556

    Limited data indicate that exogenous somatropin does not increase normal breastmilk concentrations of growth hormone and that no adverse effects are experienced by the breastfed infants of mothers who receive somatropin. Growth hormone plasma concentration naturally increase in the first 3 days postpartum, which is thought to help increase milk production. Small studies by one group of investigators found that milk output increases from 19% to 36% after a 7-day course of somatropin. Because moth…

  76. 172.
  77. 173.

    Stawerska R. · 2025 · PMID 41693185

    This paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin, somapacitan, and somatrogon. Ongoing clinical programmes are evaluating these agents in other causes of short stature that may warrant growth hormone therapy, including Turner syndrome, Noonan syndrome, children born small for gestational age (S…

  78. 174.

    Taghizadeh B, Jaafari MR, Zarghami N. · 2022 · PMID 36263321

    Reducing injection-site pain (ISP) in patients with chronic conditions such as growth hormone deficiency is a valuable strategy to improve patient compliance and therapeutic efficiency. Thus understanding different aspects of pain induction following subcutaneous injection of biotherapeutics and identifying the responsible factors are vital. Here we have discussed the effects of formulation's viscosity, concentration, osmolality, buffering agents, pH, and temperature as well as injection volume,…

  79. 175.

    Albers N, Cadarette S, Feakins B, Arregui M, Ebohon S, Lai P, Raveendran S, Kjelgaard-Hansen M, Andersen C, Zhao C, Smith A, Geffner M. · 2025 · PMID 40144813

    Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic/pharmacokinetic properties that could affect efficacy and safety. Only one LAGH available in the United States and Europe (lonapegsomatropin) delivers unmodified somatropin.…

  80. 176.

    Sävendahl L, Battelino T, Højby M, Leunbach T, Saenger P, Silverman L, Horikawa R. · 2026 · PMID 41394116

    <h4>Background</h4>Somapacitan is a once-weekly GH treatment that has shown efficacy and safety profiles equivalent to daily GH in children with GH deficiency (GHD).<h4>Objective</h4>To investigate long-term safety, efficacy, and treatment burden associated with somapacitan after 7 years (364 weeks) of treatment.<h4>Methods</h4>REAL 3 (NCT02616562) was a phase 2, randomized, open-label trial investigating the efficacy and safety of somapacitan vs daily GH in children with GHD. After 156 weeks, p…

  81. 177.

    Muroya K, Kawai M, Yamagishi H, Endo T, Pietropoli A, Ferran JM, Horikawa R. · 2026 · PMID 41285480

    Reports on long-term safety and effectiveness of daily GH replacement therapy in Japanese children with short stature due to Noonan syndrome (NS) are limited. This post-marketing, prospective, non-interventional study (ClinicalTrials.gov NCT03435627) evaluated the long‑term safety and effectiveness of daily GH therapy in this patient population. The study took place at 22 sites in Japan during November 2017-January 2022. Seventy participants were enrolled and received Norditropin<sup>®</sup> at…

  82. 178.

    Parrish C, Baird D, Redd T, Moore RP, Choi L, Zuckerman AD, Cruchelow KR. · 2026 · PMID 40891305

    <h4>Purpose</h4>Evaluating barriers that may delay or limit human growth hormone (hGH) access is important to ensure timely and equitable treatment. We examined time to hGH access and whether time to approval was associated with patient factors and impacts on patient growth.<h4>Methods</h4>This was a single-center, retrospective review of the electronic medical records of pediatric patients starting hGH treatment for an indication approved by the FDA at the Vanderbilt Pediatric Endocrinology Cli…

  83. 179.

    Heatwole CR, Luebbe E, Hamel J, Mongiovi PC, Ciafaloni E, Dilek N, Martens WB, Weber DR, Rashid H, Allen McKeown J, Smith CH, Howell S, Rosero SZ, Eichinger K, Baker LS, Dekdebrun JM, Hilbert JE, Varma A, Thornton CA, McDermott MP, Moxley RT. · 2025 · PMID 40900971

    <h4>Background and objectives</h4>Effective therapies for facioscapulohumeral muscular dystrophy (FSHD) are currently limited. Recombinant human growth hormone (rHGH) combined with testosterone (combination therapy) may have meaningful clinical effects on ambulation, strength, muscle mass, and disease burden. As such, combination therapy has the potential to limit disease progression and functional decline in individuals with muscular dystrophy. The objective of this study was to evaluate the sa…

  84. 180.

    Çetinkaya S, Eren E, Erdoğan F, Darendeliler F. · 2025 · PMID 38488050

    Recombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in institutional care. Challenges associated with daily treatment may result in missing several doses but non-adherence with treatment leads to inadequate growth response. As an inadequate growth response does not meet criteria for continuing treatment, payers…

  85. 181.

    Foo J, Maghnie M, Colao A, Vlachaki I, Colombo G. · 2019 · PMID 31692496

    <h4>Background</h4>The objective of this analysis was to evaluate the cost-consequence of recombinant human growth hormone (r-hGH) administered via the easypod auto-injector (Merck, Darmstadt, Germany) versus conventional devices in children with growth hormone deficiency in Italy.<h4>Methods</h4>A patient-level simulation, decision-analytical model was developed to estimate the average height gains and growth hormone treatment costs for a cohort of boys and girls until their bone maturation age…

  86. 182.

    Geffner ME, Ranke MB, Wajnrajch MP, Pfizer International Growth Database Strategic Executive Committee, Strategic Advisory Board, and International Board. · 2024 · PMID 38461800

    The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and gro…

  87. 183.

    Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M. · 2025 · PMID 40770534

    <h4>Purpose</h4>To describe the temporal trends in the prescription of biologics in Japan, with additional analysis focusing on switching from original biologics to biosimilars at the individual and institutional levels.<h4>Methods</h4>Using the JMDC claims database from January 2005 to May 2024, we identified patients who received at least one prescription for 17 biologics (original biologics or biosimilars). We elucidated the monthly trends in the proportions of original biologics and biosimil…

  88. 184.

    Al Jneibi SS, Taha F, Hammouri M, Allami Z, Weber S, Aljubeh J, Al Remeithi S. · 2025 · PMID 40464049

    Early diagnosis of the pathological cause, if any, of short stature in children can lead to prompt intervention with recombinant growth hormone (rGH) treatment, potentially allowing them to achieve their true genetic height potential. However, it is crucial to identify children most likely to benefit from rGH treatment.<h4>Methods</h4>This cross-sectional, retrospective study provides a broad overview of rGH prescribing patterns and evaluates both short- and long-term treatment outcomes in child…

  89. 185.

    Levshtein A, Sharkia M, Shimshi-Barash M, Almagor T, Albertsson-Wikland K, Hochberg Z, Pillar G, German A. · 2025 · PMID 40034226

    <h4>Context</h4>Physiological growth hormone is secreted during slow-wave sleep. Traditionally, growth hormone (GH) therapy is given in daily GH injections before sleep. While morning and evening GH injections produce comparable effects on growth and IGF-1 levels, the evening schedule better imitates the physiological diurnal pattern of GH secretion and action. However, the inflexibility of bedtime injection schedules, coupled with the discomfort and psychological distress associated with the in…

  90. 186.

    Fleseriu M, Jorgensen J, Yuen K, Hoybye C, Mao M, Kang J, Song W, Komirenko A, Shu A, Beckert M. · 2021

    Abstract BackgroundAdult GHD results from insufficient growth hormone (GH) secretion from the anterior pituitary gland and may represent either a continuation of childhood-onset GHD or GHD acquired during adulthood. Clinically, adult GHD is associated with central adiposity, decreased lean muscle mass, increased fat mass, decreased bone mineral density, and reduced quality of life. Current standard of care consists of GH replacement via daily injections. Lonapegsomatropin is a long-acting prodru…

  91. 187.

    Aleidi FA, Alomair S, Alharbi H, AlSalamah N, AlEnazi L. · 2025 · PMID 41020019

    Refrigeration is essential for maintaining the stability and efficacy of many pharmaceuticals, including vaccines, biologics, and certain antibiotics. However, unintentional exposure of refrigerated medications to room temperature may occur during transport delays, power outages, or handling errors, raising concerns about compromised potency and patient safety. Despite frequent real-world cold chain breaches, evidence-based guidance on acceptable room temperature excursions remains limited. This…

  92. 188.

    Chapman SR, Fitzpatrick RW, Aladul MI. · 2017 · PMID 28400458

    <h4>Objective</h4>The patent expiry of a number of biological medicines and the advent of biosimilars raised the expectations of healthcare commissioners that biosimilars would reduce the high cost of these medicines and produce potential savings to the NHS. We aimed to examine the prescribing pattern of different growth hormone preparations (ready to use and reconstitution requiring) in primary and secondary care in England to determine relative rates of decrease or increase and identify the po…

  93. 189.
  94. 190.

    Loftus J, Yaworsky A, Roland CL, Turner-Bowker D, McLafferty M, Su S, Lamoureux RE. · 2022 · PMID 36449502

    <h4>Background</h4>Daily injections of recombinant human growth hormone are the standard of care to treat growth failure due to pediatric growth hormone deficiency (GHD). While effective, daily injections are burdensome and can compromise adherence. In recent years, novel injection treatments requiring less frequent administration for growth hormone deficiency (GHD) have been developed. A targeted, pragmatic literature review was conducted to summarize and document the patient experience of movi…

  95. 191.

    Liu S, Lu W, Yang L, Tong X, Xu X, Li H. · 2025 · PMID 41460760

    BACKGROUND Translocase of the outer mitochondrial membrane 7 (TOMM7) encodes a subunit of the mitochondrial translocase complex, which has a critical role in stabilizing the complex and regulating mitochondrial function. Rare individual case reports have identified homozygous TOMM7 mutations associated with Garg-Mishra progeroid syndrome (GMPGS), characterized by dwarfism, facial dysmorphia, developmental delay, and macular scarring. However, few therapeutic interventions have been documented. C…

  96. 192.

    Graber EG, Hosseini SMH, Wilson DM, Rogol AD. · 2025 · PMID 40012910

    Human growth hormone (hGH) has been in clinical use for children with GH deficiency (GHD) since the late 1950s. The original formulations were considered very safe with few adverse events reported. That changed remarkably in 1985 when the first patients with GHD, who had been treated with cadaveric hGH, were diagnosed with Creutzfeldt-Jakob disease (CJD). Fortunately, that same year a robust supply of recombinant hGH was released to the market whose adverse event profile did not include CJD. Pat…

  97. 193.

    Kildemoes RJ, Backeljauw PF, Højby M, Blair JC, Miller BS, Mori J, Lyauk YK. · 2023 · PMID 37818403

    <h4>Context</h4>Growth hormone (GH) replacement therapy improves longitudinal growth and adult height in children with GH deficiency (GHD). GH stimulates insulin-like growth factor (IGF)-I release, the biomarker used for monitoring GH activity during treatment.<h4>Objective</h4>This study aims to provide model-based insights into the dose-IGF-I responses of once-weekly somapacitan, a novel long-acting GH, compared with daily GH in children with GHD.<h4>Methods</h4>Analyses included dosing inform…

  98. 194.

    Bilha SC, Preda C, Leustean L, Akad N, Matei A, Ungureanu MC. · 2025 · PMID 41464859

    Linear growth is traditionally attributed to the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis, yet "growth without GH" is documented. We report five patients with severe GH deficiency-one congenital and four acquired, who reached normal or tall stature despite persistently low IGF-1. All patients had obesity and metabolic complications (insulin resistance, dyslipidemia, and/or fatty liver). Catch-up or sustained growth occurred before or independent of sex-steroid replacement in…

  99. 195.

    Grimberg A, Kanter GP. · 2019 · PMID 31637343

    <h4>Objective</h4>To investigate trends in prevalence and expenditures of growth hormone (GH) use by US youth in the last 15 years, a period during which the US Food and Drug Administration (FDA) approved GH treatment of idiopathic short stature (ISS), and insurers imposed greater barriers to GH treatment reimbursements.<h4>Design</h4>With the use of 2001 to 2016 OptumInsight commercial claims data, we analyzed trends in claims of GH drugs among beneficiaries aged 0 to 18 years (n = 38,857 benef…

  100. 196.

    2022

    Abstract <h4>Background</h4> Somatrogon is a long-acting recombinant human growth hormone (hGH) currently in development as a once-weekly injectable treatment for children with growth hormone deficiency (GHD). In a phase 2 (NCT01592500) and a phase 3 (NCT02968004) study, patients received either once-weekly somatrogon or once-daily Genotropin. <h4>Aims</h4> Compare the phase 2 and 3 study results with growth data from published literature and a database of children treated with once-daily Genotr…

  101. 197.

    Ogata T, Fukami M, Tanizawa K, Yamamoto T, Sato Y, Hirai H, Takasao N, Ibaraki R, Noda M. · 2024 · PMID 38572386

    We conducted a randomized phase 3 study to investigate the efficacy and safety of GH treatment in prepubertal Japanese patients with short stature due to <i>SHOX</i> deficiency. The patients were randomly allocated to the GH-GH group (n = 10), in which the patients were treated with GH (0.35 mg/kg/wk) subcutaneously once daily for 24 mo, or the no-treatment (NT)-GH group (n = 9), in which the patients were untreated for the first 12 mo and then administered the same dosage of GH for the next 12…

  102. 198.

    Beck-Peccoz P, Höybye C, Simsek S, Stalla G, Murray RD, Esmael A, Urosevic D, Boldea A, Zabransky M. · 2024 · PMID 39659948

    <h4>Purpose</h4>Long-term studies are needed to investigate the safety of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD) in routine practice. The objective of this study was to evaluate the safety and effectiveness of biosimilar rhGH (somatropin; Omnitrope<sup>®</sup>) in adults with GHD.<h4>Methods</h4>PAtients TReated with Omnitrope (PATRO) Adults was a post-marketing surveillance study conducted across Europe. The primary objective was the safety…

  103. 199.
  104. 200.

    Shah A, Ravi B, Tomescu S, Catapano M, Burkhart TA, Whyne C, Kiss A, Marks P, Wasserstein DN. · 2026 · PMID 41638751

    <h4>Introduction</h4>The management of active patients with symptomatic knee osteoarthritis (KnOA) who are too young for total knee arthroplasty poses a specific challenge to clinicians. Research studies show that improving quadriceps muscle strength improves pain and function; however, aspects of the disease render it difficult for patients to achieve and maintain improvements. Recombinant human growth hormone (rHGH) is shown to increase the magnitude and duration of muscle growth when combined…

  105. 201.

    2022

    Abstract <h4>Background</h4> Children with growth hormone deficiency (GHD) are treated with recombinant human growth hormone (rhGH), usually administered as a daily subcutaneous injection. Long-acting hGH (LAGH) treatments (approved and in development) have the potential to improve adherence and treatment outcomes. Somatrogon is a LAGH currently being developed as a once-weekly injectable treatment for GHD. The Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES) study was initiated…

  106. 202.

    Steiner M, Frank J, Saenger P. · 2023 · PMID 36967745

    After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency. In 1985, recombinant GH became available, and the modalities of GH therapies changed dramatically as the supply was unlimited. New indications for GH in pediatrics and adult medicine were developed. Treatment was daily. Now in 2021 long-acting GH (LAGH) became available the world over making GH therapy more patient-friendly and e…

  107. 203.

    Coutant R, Benchikh N, Linglart A, Nicolino M, Salles JP. · 2025 · PMID 41347137

    <h4>Introduction</h4>Recombinant human growth hormone (rhGH) treatment for short children born small for gestational age (SGA) is effective in improving height outcomes. Determinants of height response to rhGH treatment have been identified using multiple regression analyses. Although adverse events (AEs) associated with treatment have been described, determinants of AE occurrence are not well known.<h4>Methods</h4>This analysis used safety data collected between 2007 and 2018 in an observationa…

  108. 204.

    2022

    Abstract <h4>Background</h4> The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in the real-world setting. Data were collected in the US and Europe from 2006 to 2016. <h4>Objective</h4> To determine predictors of response to daily growth hormone (GH) for height outc…

  109. 205.
  110. 206.

    Luo X, Hou L, Zhong Y, Zhao S, Chen X, Dong Q, Du H, Lu H, Yang Y, Wu X, Luo F, Chen R, Xu Z, Ma Y, Song W, Feng M, Gu X, Qiu W. · 2025 · PMID 39513569

    <h4>Objective</h4>Children born small for gestational age (SGA) are at increased risk of health issues. This study evaluated the efficacy, safety and optimal dose of PEGylated-recombinant human growth hormone (PEG-rhGH) in these children.<h4>Design</h4>In this multicentre, randomised, open-label, Phase 2 trial conducted at nine clinical sites in China, patients were randomised 1:1 to receive subcutaneous injections of PEG-rhGH at 0.1 mg/kg/week (low dose) or 0.2 mg/kg/week (high dose) for 52 wee…

  111. 207.

    Thornton P, Hofman P, Maniatis A, Aghajanova E, Chertok E, Korpal-Szczyrska M, Giorgadze E, Kovalenko T, Shu A, Karpf D, Beckert M, Leff J. · 2019

    Abstract TransCon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Phase 3 heiGHt TrialBackground TransCon Growth Hormone is a sustained-release recombinant human growth hormone (hGH; somatropin) prodrug in development as a long-acting GH (LAGH) for children with growth hormone deficiency (GHD). In its prodrug form, TransCon hGH is inactive with hGH transiently bound to a TransCon carrier via a TransCon linker. Upon injection and triggered by physiological p…

  112. 208.

    Baumgartner C, Metz M, Beghini M, Pfleger L, Tosin A, Koldyka O, Beiglböck H, Fellinger P, Vila G, Luger A, Kautzky-Willer A, Freudenthaler A, Baumgartner-Parzer S, Stangl H, Krssak M, Carli F, Infelise P, Gastaldelli A, Scherer T, Krebs M, Wolf P. · 2025 · PMID 40215215

    <h4>Context</h4>Growth hormone (GH) reduces intrahepatic lipids (IHL) according to investigations in healthy volunteers and patients with acromegaly, a disease characterized by long-term GH excess.<h4>Objective</h4>This study investigated underlying antisteatotic pathways stimulated by short-term modulation of GH action.<h4>Methods</h4>Ten healthy male volunteers (26 ± 5 years, body mass index [BMI] 23 ± 3.4 kg/m2) were assessed before and after 1 week of daily subcutaneous treatment with either…

  113. 209.

    Miller BS, Blair JC, Rasmussen MH, Maniatis A, Mori J, Böttcher V, Kim HS, Bang RB, Polak M, Horikawa R. · 2023 · PMID 37406251

    <h4>Context</h4>Somapacitan is a long-acting GH derivative for treatment of GH deficiency (GHD).<h4>Objective</h4>Evaluate the efficacy and tolerability of somapacitan in children with GHD after 2 years of treatment and after the switch from daily GH.<h4>Design</h4>A randomized, multinational, open-labelled, controlled parallel group phase 3 trial, comprising a 52-week main phase and 3-year safety extension (NCT03811535).<h4>Setting</h4>Eighty-five sites across 20 countries.<h4>Patients</h4>A to…

  114. 210.

    Karamonová L, Procházková B, Volný M, Nemeškalová A, Sýkora D, Kuchař M, Fukal L, Holubová B. · 2025 · PMID 40519661

    The use of human growth hormone (hGH) by athletes remains widespread despite being banned by the World Anti-Doping Agency (WADA). Current commercial ELISA kits for the determination of hGH are predominantly based on the sandwich format of this method, which allows the analysis of the whole hGH molecules, but not their fragments. The abuse of these fragments by athletes is the current trend in doping. Therefore, a competitive ELISA format is needed; however, only a limited number of kits on the m…

Case Reports

3
  1. 211.

    Mann J, Caruana D, Luo E, Gottesman E, et al. · Cureus · 2022 · PMID 36110455

    Adult growth hormone (GH) deficiency is rare and requires replacement with extrinsic/synthetic injection. GH hypersensitivity has been reported; specifically, atopic patients may develop rashes from somatotropin therapy. Allergic and non-allergic skin reactions to recombinant human GH are uncommon and infrequently reported. We describe a graded-dose challenge with intravenous Norditropin® in a 65-year-old atopic adult woman who developed a severe whole-body rash with Norditropin FlexPro® adminis…

  2. 212.

    Ruvalcaba RH, Castro-Magana M, Angulo M · Journal of pediatric endocrinology & metabolism : JPEM · 1996 · PMID 9004178

    Prolactin secreting pituitary adenomas are a rare finding in prepubertal children /1/. As in adults, their incidence is higher in girls than in boys; however, the macroadenomas are predominant in boys /20-16/. Two prepubertal boys who presented with short stature and linear growth deceleration were diagnosed to have prolactin secreting pituitary macroadenoma associated with growth hormone (GH) deficiency. They were treated with bromocryptine and exogenous recombinant hGH. They achieved a normal…

  3. 213.

    Nishi Y, Masuda H, Nishimura S, Kihara M, et al. · Acta endocrinologica · 1990 · PMID 1969217

    Three Japanese patients with isolated growth hormone deficiency from two different families were shown to be homozygous for deletion of the structural gene for human growth hormone (hGH-I gene). These three patients had the same restriction fragment length polymorphism haplotypes. In patient No. 1, the growth rate initially responded well to pituitary human growth hormone, but growth rapidly ceased concomitantly with the development of high levels of anti-hGH antibodies. He again responded well…

Curated sources on file

9
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.

Continue reading